- Frencken (SGX:E28)’s 9M25 earnings of S$29.8m (+9% y-o-y) formed 75% of our full-year forecast, in line with expectations. The results improvement was driven by a 13% y-o-y revenue growth as well as stable net margin.
- - Read this at SGinvestors.io -
Revenue growth across three key segments offset by drop in analytical life sciences revenue.
- Frencken’s 3Q25 revenue grew 7% y-o-y, mainly driven by the semiconductor (+8% y-o-y), medical (+6% y-o-y) and industrial automation (+51% y-o-y) segments. Growth in the semiconductor segment was driven by stronger Asia sales, due to a broader product portfolio and a recovery in demand.
- Revenue of the analytical life sciences (-8% y-o-y) segment fell on lower customer demand in Europe, while that of the automotive (1% y-o-y) segment remained stable.
Outlook downgraded but y-o-y revenue growth still expected despite market pressure.
- - Read this at SGinvestors.io -
- Nonetheless, Frencken still expects y-o-y revenue growth for 2025.
Expect 2H25 revenue to be marginally lower h-o-h vs 1H25 (reduced from broadly stable in the quarter before).
- Read more at SGinvestors.io.
Above is an excerpt from a report by UOB Kay Hian Research.
Clients of UOB Kay Hian may be the first to access the full PDF report @ https://www.utrade.com.sg/.
John Cheong UOB Kay Hian Research | https://research.uobkayhian.com/ 2025-11-18
Read also UOB's most recent report:
2026-05-20 Frencken Group - Expect A Strong 2H26 and 2027 Driven By Semiconductor Segment.
Price targets by 4 other brokers at Frencken Target Prices.
Listing of research reports at Frencken Analyst Reports.
Relevant links:
Frencken Share Price History,
Frencken Announcements,
Frencken Dividend Payout Dates & Corporate Actions,
Frencken News
